Drug Approval | September 22, 2024
Briefs: Biocon, Aarti Drugs and Glenmark Pharmaceuticals
Glenmark Pharmaceuticals Limited has informed that the USFDA has issued Form 483 with zero observations
Glenmark Pharmaceuticals Limited has informed that the USFDA has issued Form 483 with zero observations
Stable profits, low leverage to keep credit profiles comfortable
USFDA concludes inspection of Dr. Reddy's Laboratories R&D centre in Bachupally with zero observation
Takeda has granted Lupin non-exclusive patent licensing rights to commercialize Vonoprazan in India
Tecentriq Hybreza provides patients and physicians with greater flexibility of treatment options while showing safety and efficacy consistent with intravenous
The sANDA was submitted as “Prior Approval Supplement” for addition of an alternate drug product manufacturing, labeling, packaging, and testing facility
Investment in new plant meets increasing demand for functional excipients for oral drug delivery
Wanbury receives CEP approval from EDQM for launch of Dextromethorphan API
Agreement further expands Aptar Pharma’s leading respiratory portfolio
The companies will combine Nanoform’s Biologics platform with the Celanese VitalDose Drug Delivery platform to further optimize controlled release of biologics
Subscribe To Our Newsletter & Stay Updated
